Minhao Lv1, Huihui Guo2, Chao Wang3, Peiqi Tian1, Youzhao Ma1, Xiuchun Chen1, Suxia Luo4. 1. Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. 2. Department of General Surgery, The Jiyuan People's Hospital, Jiyuan, China. 3. Department of General Surgery, The Huaxian People's Hospital, Huaxian, China. 4. Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Abstract
BACKGROUND: This study aimed to compare the real-world efficacy and safety of the TCbHP regimen (docetaxel, carboplatin, trastuzumab and pertuzumab) and the THP regimen (docetaxel, trastuzumab and pertuzumab) as neoadjuvant therapy for Chinese patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHODS: We compared efficacy and safety outcomes from 72 Chinese patients with HER2-positive breast cancer who underwent neoadjuvant dual HER2 blockade plus TCb or T chemotherapy and surgery between March 2019 and June 2020. RESULTS: All 72 patients were women (32-76 years old) and the overall pathological complete response (pCR) rate was 70.8% (51/72). The pCR rates were 76.1% (35/46) for the TCbHP regimen and 61.5% (16/26) for the THP regimen (P=0.28). Univariate analyses revealed that pCR was associated with clinical T classification (P=0.024), AJCC stage (P=0.042), estrogen receptor (ER) status (P=0.002), progesterone receptor (PR) status (P=0.035), Ki-67 index (P<0.001), and immunohistochemical HER2 status (P<0.001). Multivariate analyses revealed that pCR was independently predicted by ER status (OR: 0.227, 95% CI: 0.053-0.852; P=0.032) and immunohistochemical HER2 status (OR: 43.673, 95% CI: 6.801-875.86; P<0.001). The common adverse events for both regimens included neutropenia, anemia, thrombocytopenia, nausea, and diarrhea. Relative to the THP group, the TCbHP group had higher frequencies of grade 3-4 thrombocytopenia (17% vs. 0%, P=0.044) and grade 3-4 diarrhea (15% vs. 0%, P=0.044). Both regimens had very good cardiac safety. CONCLUSIONS: These results suggest that both TCbHP and THP regimens may be useful neoadjuvant treatments for high-risk early or locally advanced HER2-positive breast cancer. Both regimens had generally good safety outcomes, although clinicians should be aware of the risks of grade 3-4 thrombocytopenia and diarrhea during TCbHP treatment. Elderly patients who require neoadjuvant therapy may benefit from 6 cycles of THP treatment, based on its good efficacy and mild adverse events. 2020 Gland Surgery. All rights reserved.
BACKGROUND: This study aimed to compare the real-world efficacy and safety of the TCbHP regimen (docetaxel, carboplatin, trastuzumab and pertuzumab) and the THP regimen (docetaxel, trastuzumab and pertuzumab) as neoadjuvant therapy for Chinese patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHODS: We compared efficacy and safety outcomes from 72 Chinese patients with HER2-positive breast cancer who underwent neoadjuvant dual HER2 blockade plus TCb or T chemotherapy and surgery between March 2019 and June 2020. RESULTS: All 72 patients were women (32-76 years old) and the overall pathological complete response (pCR) rate was 70.8% (51/72). The pCR rates were 76.1% (35/46) for the TCbHP regimen and 61.5% (16/26) for the THP regimen (P=0.28). Univariate analyses revealed that pCR was associated with clinical T classification (P=0.024), AJCC stage (P=0.042), estrogen receptor (ER) status (P=0.002), progesterone receptor (PR) status (P=0.035), Ki-67 index (P<0.001), and immunohistochemical HER2 status (P<0.001). Multivariate analyses revealed that pCR was independently predicted by ER status (OR: 0.227, 95% CI: 0.053-0.852; P=0.032) and immunohistochemical HER2 status (OR: 43.673, 95% CI: 6.801-875.86; P<0.001). The common adverse events for both regimens included neutropenia, anemia, thrombocytopenia, nausea, and diarrhea. Relative to the THP group, the TCbHP group had higher frequencies of grade 3-4 thrombocytopenia (17% vs. 0%, P=0.044) and grade 3-4 diarrhea (15% vs. 0%, P=0.044). Both regimens had very good cardiac safety. CONCLUSIONS: These results suggest that both TCbHP and THP regimens may be useful neoadjuvant treatments for high-risk early or locally advanced HER2-positive breast cancer. Both regimens had generally good safety outcomes, although clinicians should be aware of the risks of grade 3-4 thrombocytopenia and diarrhea during TCbHP treatment. Elderly patients who require neoadjuvant therapy may benefit from 6 cycles of THP treatment, based on its good efficacy and mild adverse events. 2020 Gland Surgery. All rights reserved.
Entities:
Keywords:
Breast cancer; neoadjuvant chemotherapy; pathological complete response; safety
Authors: Andreas Schneeweiss; Stephen Chia; Tamas Hickish; Vernon Harvey; Alexandru Eniu; Maeve Waldron-Lynch; Jennifer Eng-Wong; Sarah Kirk; Javier Cortés Journal: Eur J Cancer Date: 2017-12-08 Impact factor: 9.162
Authors: Gunter von Minckwitz; Marion Procter; Evandro de Azambuja; Dimitrios Zardavas; Mark Benyunes; Giuseppe Viale; Thomas Suter; Amal Arahmani; Nathalie Rouchet; Emma Clark; Adam Knott; Istvan Lang; Christelle Levy; Denise A Yardley; Jose Bines; Richard D Gelber; Martine Piccart; Jose Baselga Journal: N Engl J Med Date: 2017-06-05 Impact factor: 91.245
Authors: S M Swain; A Schneeweiss; L Gianni; J J Gao; A Stein; M Waldron-Lynch; S Heeson; M S Beattie; B Yoo; J Cortes; J Baselga Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976
Authors: Sandra M Swain; David Miles; Sung-Bae Kim; Young-Hyuck Im; Seock-Ah Im; Vladimir Semiglazov; Eva Ciruelos; Andreas Schneeweiss; Sherene Loi; Estefanía Monturus; Emma Clark; Adam Knott; Eleonora Restuccia; Mark C Benyunes; Javier Cortés Journal: Lancet Oncol Date: 2020-03-12 Impact factor: 41.316
Authors: Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer Journal: N Engl J Med Date: 2018-12-05 Impact factor: 176.079
Authors: Sara A Hurvitz; Miguel Martin; Kyung Hae Jung; Chiun-Sheng Huang; Nadia Harbeck; Vicente Valero; Daniil Stroyakovskiy; Hans Wildiers; Mario Campone; Jean-François Boileau; Peter A Fasching; Karen Afenjar; Gonzalo Spera; Vanesa Lopez-Valverde; Chunyan Song; Peter Trask; Thomas Boulet; Joseph A Sparano; W Fraser Symmans; Alastair M Thompson; Dennis Slamon Journal: J Clin Oncol Date: 2019-06-03 Impact factor: 44.544
Authors: Benjamin James Hall; Ajay Ashok Bhojwani; Helen Wong; Andrea Law; Helen Flint; Eliyaz Ahmed; Helen Innes; Joanne Cliff; Zaf Malik; Julie Elizabeth O'Hagan; Allison Hall; Rajaram Sripadam; Shaun Tolan; Zulfiqar Ali; Clare Hart; Douglas Errington; Farida Alam; Rosa Giuliani; Shaveta Mehta; Sheena Khanduri; Nicky Thorp; Richard Jackson; Silvia Cicconi; Carlo Palmieri Journal: Breast J Date: 2022-06-30 Impact factor: 2.269
Authors: Agnieszka Irena Jagiełło-Gruszfeld; Magdalena Rosinska; Małgorzata Meluch; Katarzyna Pogoda; Anna Niwinska; Renata Sienkiewicz; Aleksander Grous; Paweł Winter; Zbigniew I Nowecki Journal: Cancers (Basel) Date: 2022-02-26 Impact factor: 6.639